Biogen boosts multiple sclerosis holding with Alkermes license

(Reuters) – Biogen Inc said on Monday it has licensed Alkermes Plc’s multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *